2016 ACVIM Forum Research Abstract Program

Medical records from 1995-2014 at a USA Veterinary Teaching Hospital were retrospectively searched for dogs with immune mediated diseases administered leflunomide. Data that were extracted from the medical records included signalment, bodyweight, underlying indication for leflunomide, dose of leflunomide, treatment duration, concurrent medications, treatment response, and adverse events. Dogs with immune mediated polyarthritis (IMPA) were assessed for response to treatment on the basis of clinical signs of IMPA and physical examination findings. Dogs with immune mediated thrombocytopenia (IMTP) were assessed for response to treatment based on platelet count. A dog with cutaneous histiocytosis (CH) was assessed for treatment response on the basis of gross appearance of the skin lesion.